Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. reports developments in precision medicine for transplant patients and caregivers. The company’s updates center on non-invasive molecular testing for heart, kidney, and lung transplantation, including AlloSure, AlloMap, HeartCare, and related evidence generation for post-transplant surveillance, risk assessment, and longitudinal patient management.
CareDx news also covers operating and financial results for testing services and patient and digital solutions, product and platform launches such as VANTx clinical data analytics, clinical conference presentations, material agreements, and Nasdaq-related governance matters including inducement equity awards.
CareDx (Nasdaq: CDNA) announced clinical validation of AlloHeme, an AI‑powered, NGS blood test to surveil relapse in AML and MDS after allogeneic HCT.
The ACROBAT study (198 subjects, 40 relapse events) showed 85% sensitivity, 92% specificity, 95% NPV, 79% PPV, AUC 0.89, and a median 41‑day lead time. CareDx expects CLIA readiness in 2026, commercial launch in 2027, and payer coverage in 2028.
CareDx (Nasdaq: CDNA) will report fourth quarter and full year 2025 financial results after market close on Tuesday, February 24, 2026. A webcast and conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET.
Live and archived webcast access is available on the Events & Presentations section of CareDx's Investor Relations website, and telephone participation requires registration to receive a dial-in number and unique PIN.
CareDx (Nasdaq: CDNA) will present pivotal clinical validation data from the ACROBAT study of AlloHeme at the 2026 Tandem Meetings (Feb 4-7) and will host an investor webcast Feb 12. The ACROBAT trial is a prospective, blinded, multi-center study (11 U.S. centers) reporting complete 24-month follow-up for relapse surveillance after allogeneic HCT in AML and MDS.
The oral presentation includes 24-month results; the webcast will review clinical validation data and the commercial launch timeline for AlloHeme.
CareDx (Nasdaq: CDNA) will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT on Tuesday, February 10, 2026. The company is described as focused on precision medicine and on discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers.
CareDx (Nasdaq: CDNA) reported preliminary, unaudited results for Q4 and full year 2025. Q4 revenue ~ $108M (+25% YoY) with testing services revenue ~ $78M (+23% YoY) and testing volume ~ 53,000 (+17% YoY). FY2025 revenue ~ $380M (+14% YoY) with testing services ~ $274M (+10% YoY), testing volume ~ 200,000 (+14% YoY), patient & digital solutions ~ $57M (+31% YoY) and product revenue ~ $48M (+19% YoY).
Average revenue per test ~ $1,470 (includes ~ $5M prior period revenue). cash, cash equivalents and marketable securities ~ $200M at 12/31/2025. Share repurchases: $12M in Q4 (773,000 shares) and $88M for year (5.8M shares) at average prices shown. Results are preliminary and may change after audit.
CareDx (Nasdaq: CDNA) and 10x Genomics (Nasdaq: TXG) launched ImmuneScape, a multiomics research program to map immune biology in transplant rejection and therapeutic response.
The collaboration will use 10x Xenium spatial and Chromium Flex single cell platforms to profile FFPE biopsy samples at cellular resolution, focusing on antibody-mediated rejection (AMR) and microvascular inflammation (MVI). Insights are intended to support future diagnostic development and to correlate tissue-level immune architecture with clinical outcomes, including response to anti-CD38 therapies.
CareDx (Nasdaq: CDNA) announced inducement restricted stock unit (RSU) awards granted as an employment inducement under Nasdaq Listing Rule 5635(c)(4). On December 19, 2025, the company granted RSUs to 39 new employees totaling 80,425 shares under the 2025 Inducement Equity Incentive Plan. The RSUs vest over four years: 25% at the first anniversary of each vesting commencement date and then 1/16th each quarter, subject to continued service. CareDx provided the disclosure to comply with Nasdaq rule requirements.
CareDx (Nasdaq: CDNA) announced the third SHORE manuscript published in the Journal of Heart and Lung Transplantation on November 24, 2025, reporting prognostic value for HeartCare® molecular testing in heart transplant recipients.
The study of 1,934 patients across 59 centers found that positive HeartCare results (both AlloMap and AlloSure Heart) at 2–6 months post‑transplant were linked to a nearly twofold higher one‑year cumulative incidence of graft dysfunction and cardiovascular death (15.5% vs. 8.5% or lower; p=0.009). A positive HeartCare result at any time (2 months–5 years) was associated with a threefold increase in 30‑day risk of those outcomes. Elevated molecular signals identified risk even when biopsies were normal, supporting HeartCare's independent prognostic role.
CareDx (Nasdaq: CDNA) will participate in two investor conferences in late 2025: a Fireside Chat at the Stephens Investment Conference in Nashville on Wednesday, November 19, 2025 at 8:00 AM CT, and a presentation at the Piper Sandler Healthcare Conference in New York on Wednesday, December 3, 2025 at 4:30 PM ET.
Live and archived webcasts of both presentations will be available in the Events and Presentations section of CareDx investor relations at investors.caredx.com.
CareDx (Nasdaq: CDNA) announced inducement equity awards on November 4, 2025 under its 2025 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The company granted restricted stock units (RSUs) to 49 new employees totaling 113,250 shares and separately granted 88,180 RSUs to Dr. Jeffrey Teuteberg upon his appointment as Chief Medical Officer. The RSUs vest over four years: 25% on the first anniversary of each recipient’s vesting commencement date and thereafter 1/16th each quarter, subject to continued service.